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Abstract
 
The accumulation of immunoglobulin (Ig)A antibody-secreting cells (ASCs) in the lactating
mammary gland leads to secretion of antibodies into milk and their passive transfer to the suck-
ling newborn. This transfer of IgA from mother to infant provides transient immune protection
against a variety of gastrointestinal pathogens. Here we show that the mucosal epithelial che-
mokine CCL28 is up-regulated in the mammary gland during lactation and that IgA ASCs
from this tissue express CCR10 and migrate to CCL28. In vivo treatment with anti-CCL28
antibody blocks IgA ASC accumulation in the mammary gland, inhibiting IgA antibody secre-
tion into milk and the subsequent appearance of antibody in the gastrointestinal tract of nursing
neonates. We propose that CCL28 is a key regulator of IgA ASC accumulation in the mam-
mary gland and thus controls the passive transfer of IgA antibodies from mother to infant.
Key words: cell trafﬁcking • common mucosal immune system • chemokine • 
passive immunity • milk
 
Introduction
 
The gut serves as a portal of entry for a myriad of patho-
gens. Several mechanisms of protection have evolved to
protect the gut from microbes, including effector T cells
and antibody-secreting cells (ASCs). IgA ASCs are of par-
ticular importance because IgA antibodies are secreted
across the gut epithelium into the intestinal lumen where
they can neutralize pathogens and toxins (1, 2). The gas-
trointestinal tract of the neonate is particularly vulnerable
to infection because the newborn is immunologically naive
for the first several days of life, until effector T cells and
ASCs are generated and disseminated throughout the body.
The adaptive immune system of the mother can provide
passive protection to the suckling newborn through anti-
bodies ingested in the mother’s milk (3, 4). During late
pregnancy and lactation, maternal IgA ASCs primed in the
gut and respiratory tract, home to the mammary gland
(5–7), secreting antibody into the milk for passage to the
gastrointestinal tract of the nursing neonate (8). Secretory
IgA is resistant to gastrointestinal enzymes, allowing the pas-
sage of functional IgA through the infant’s gastrointestinal
tract (9). The transfer of maternal antibodies to the nursing
neonate provides transient immune protection to patho-
gens previously encountered by the mother, and contrib-
utes to the dramatically reduced infant mortality levels in
children who are breast fed compared with those who are
formula fed in developing countries (10).
The participation of chemoattractants in the mammary
gland IgA response is suggested by early studies reporting
chemotactic activity for IgA ASCs in mouse colostrum (11).
It is now clear that chemoattractant cytokines (chemokines)
play a vital role in lymphocyte trafficking, and participate as
key players in the multistep processes of lymphocyte re-
cruitment from the blood into tissues (12). Recent studies
have led to the hypothesis that the epithelial chemokines
CCL25 and CCL28 mediate IgA ASC trafficking to gas-
trointestinal and respiratory mucosal sites (13–15). The role
of these or other chemokines in IgA ASC migration to the
mammary gland has not been examined. In regard to mam-
mary gland homing, CCL28 is a particularly attractive can-
didate because most IgA ASCs in the body express the
CCL28 receptor CCR10, migrate to CCL28 in vitro (13,
14), and CCL28 is found in milk (16).
In this report, we show that CCL28 is up-regulated in
the mammary gland during lactation, and demonstrate
that antibodies to CCL28 inhibit the accumulation of IgA-
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producing cells in the mammary gland, providing direct
evidence that CCL28 can control local mucosal IgA ASC
responses. Finally, we show that CCL28-mediated IgA
ASC accumulation is required for efficient transfer of ma-
ternal IgA antibodies to the suckling neonate.
 
Materials and Methods
 
PCR.
 
Total RNA was collected from the mammary gland of
BALB/c mice (the fourth abdominal mammary gland was used in
all experiments) at various stages of pregnancy and lactation using
the RNeasy kit (QIAGEN). All PCR reactions were performed
using an RNA PCR core kit (Applied Biosystems) according to
the manufacturer’s recommendations. The following primers were
used: CCL28: sense ATGCAGCAAGCAGGGCTCACACTC,
antisense ACGAGAGGCTTCGTGCCTGTGTGT; GAPHD:
sense CCATGGAGAAGGCTGGGG, antisense CAAAGTTG-
TCATGGATGACC; CCR10: sense CCCGAAAGCCTCAC-
GCAGACTG, antisense GGAGCAGCCTCCGCAGGTCCC-
GGCGG; and CCR3: sense TCCACTGTACTCCCTGGTGT,
antisense GACTGCAGGAAAACTCTCCA. PCR product was
run on a 1.5% agarose gel and visualized with ethidium bromide
staining.
 
Chemotaxis and Cell Staining.
 
Small intestine lamina propria
lymphocytes and mammary gland lymphocytes were isolated by
collagenase digestion of the tissue (after removal of Peyer’s
patches and lymph nodes, respectively) as described previously
(14). All tissues were collected from lactating mice 9 d postpar-
tum. Chemotaxis assays were performed and migrated lympho-
cytes were enumerated using a bead-counting method as de-
scribed previously (14). IgA ASCs were identified and defined as
described previously (14). CCL28–Ig binding was performed in
the presence of 5 
 
 
 
g normal goat IgG using a mCCL28-hIgG
chimera detected with PE-conjugated donkey anti–human IgG
(Jackson ImmunoResearch Laboratories) as described previously
(14). Negative controls were performed by inhibiting CCL28–Ig
binding with 5 
 
 
 
g polyclonal goat anti-mCCL28 (R&D Sys-
tems). The following rat anti–mouse antibodies were used for
staining: B220 (RA3-6B2), IgA (C10-3), and TCR-
 
  
 
(H57-597;
all from BD Biosciences). Flow cytometry was performed on a
FACSCalibur (BD Biosciences) using CELLQuest software.
 
In Vivo Anti-CCL28 Blockade.
 
Female BALB/c mice in their
first pregnancy were used in all experiments. In antibody-block-
ing experiments 100 
 
 
 
g of monoclonal anti-CCL28 (R&D Sys-
tems) or IgG2b isotype control antibody was injected i.p. on days
1, 3, 5, and 7 postpartum. Mouse milk was collected on days 1
and 9. Anesthetized mice were injected i.p. with 2 U oxytocin
(Sigma-Aldrich) and milk was collected using a suction powered
milking apparatus, similar to that described previously (17). Milk
was then centrifuged at 14,000 RPM for 5 min at room tempera-
ture, the fat was discarded, and the whey portion of the milk was
stored at 
 
 
 
20
 
 
 
C until use.
 
Immunohistology.
 
8-
 
 
 
m frozen sections were fixed in cold ac-
etone for 10 min. After drying, slides were stained with FITC-
labeled anti-IgA and PE-labeled anti–TCR-
 
 
 
. Staining was visu-
alized using confocal microscopy. IgA staining lymphocytes were
counted by photographing random mammary gland sections and
visually analyzing photographs for the number of stained cells/
field of view. Cell numbers were then scaled to reflect the num-
ber of cells/mm
 
2 
 
of mammary gland tissue and data were ex-
pressed as mean 
 
  
 
SEM. Multiple tissue sections from each of
five mice were examined per treatment group.
 
ELISA.
 
ELISA plates (Nunc) were coated with 2 
 
 
 
g/ml of
capture antibody diluted in PBS and coated overnight at 4
 
 
 
C.
Milk samples were diluted in blocking buffer and incubated in
ELISA plates for 2 h at room temperature. Alkaline phosphatase–
conjugated secondary antibodies were used as detection reagents.
Antibody concentrations were determined by constructing a
standard curve of known values and calculating the microgram/
milliliter of antibody in milk or the microgram/milligram
 
 
 
of anti-
body in feces. Milk from five or more mice was used to deter-
mine antibody levels for each treatment group. 18 and 23 neo-
nates were used to determine IgA levels in the feces of pups
nursing on control- and anti-CCL28–treated mothers, respec-
tively. Data are expressed as mean 
 
  
 
SEM.
 
Statistical Methods.
 
Student’s 
 
t 
 
test was used to analyze the re-
sults, and P 
 
  
 
0.01 was considered significant.
 
Results and Discussion
 
CCL28 Is Up-regulated in the Mammary Gland during Lac-
tation.
 
Few lymphocytes are present in the mammary glands
of virgin mice and IgA ASCs are rare. IgA ASCs begin to ap-
pear late in pregnancy and increase dramatically in number
soon after the start of lactation. By the third week of lactation,
the number of IgA ASCs has increased by several hundredfold
(6, 18). We determined if the level of CCL28 expression in
the mammary gland correlates with the accumulation of IgA
ASCs. In contrast to constitutive mucosal expression reported
for salivary gland and colon (19), we found that CCL28 ex-
pression in the mammary gland is tightly regulated and inti-
mately associated with the process of lactation. CCL28 mes-
sage is not detected by semiquantitative RT-PCR in the
mammary gland of virgin mice (Fig. 1). CCL28 message is
slightly up-regulated during late pregnancy and early lactation,
correlating with the beginning of IgA ASC accumulation.
Approximately 48 h after the start of lactation, CCL28 ex-
pression rises dramatically and high levels of chemokine
mRNA are maintained throughout lactation (Fig. 1). This re-
markable up-regulation of CCL28 correlates well with the
time course of IgA ASC appearance and accumulation.
 
Mammary Gland IgA Cells Migrate to CCL28 and Express
CCR10.
 
Next, we asked whether IgA ASCs from the lac-
tating mammary gland can respond to CCL28 in in vitro
Figure 1. CCL28 expression in the mammary gland is up-regulated
during lactation. RT-PCR was performed using primers specific for
mouse CCL28 and GAPDH using mammary gland total RNA. 
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chemotaxis assays (Fig. 2 A). Mammary gland IgA ASCs
migrated approximately three times more efficiently to the
CCR10 ligands CCL28 (mean migration: 36.2 
 
  
 
5.4%
SEM) and CCL27 (not depicted), and less well to the
small intestinal chemokine CCL25 (mean migration: 12.1 
 
 
 
3.2% SEM; P 
 
  
 
0.01), which has been implicated in the
homing of CCR9-expressing IgA ASCs to the small intes-
tine (Fig. 2 A; references 15, 20, and 21). In contrast, IgA
ASCs isolated from the small intestines migrated well to
both CCL28 and CCL25 (Fig. 2 A). A CCL28–Ig fusion
protein bound specifically to the surface of most mammary
gland IgA ASCs (Fig. 2 B), confirming expression of
CCL28 receptor by the majority of IgA-expressing lympho-
cytes. The robust migration of mammary gland IgA ASCs
to CCL28 but not CCL25 may indicate that mammary
gland IgA ASCs comprise a population of lymphocytes de-
rived primarily from antigen responses in sites such as the
respiratory tract and large intestine. Small intestine–derived
ASCs, which respond well to both chemokines, could rep-
resent a minor component of mammary ASCs. CCL28 has
been shown to bind two receptors, CCR3 and CCR10
(19), but mammary gland IgA ASCs did not migrate to the
to the CCR3 ligand eotaxin (not depicted). Moreover, IgA
ASCs sorted from the mammary glands of mice 9 d postpar-
tum showed strong expression of CCR10, but no expres-
sion of CCR3 by RT-PCR (Fig. 2 C). We conclude that
mammary IgA ASCs, like IgA ASCs in the blood and other
mucosal sites, express the CCL28 receptor CCR10 (22, 23).
 
CCL28 Blockade Inhibits IgA ASC Accumulation to the
Mammary Gland and IgA Accumulation in the Milk.
 
To de-
termine whether CCL28 regulates IgA ASC accumulation
in the mammary gland and secretory IgA levels in the milk,
we treated mice with a function-blocking anti-CCL28 anti-
body and evaluated the number of IgA ASCs in the mam-
Figure 2. Mammary gland IgA ASCs migrate to CCL28, bind
CCL28–Ig chimera, and express CCR10. Lymphocytes were isolated
from the mammary gland and small intestine of lactating mice. (A) Migra-
tion of mammary gland and small intestine IgA ASCs to CCL25 (black
bars), CCL28 (hatched bars), and CXCL12 (white bars). **, differences
were statistically significant (P   0.01) between CCL28 and CCL25 mi-
gration. Data are expressed as mean   SEM. (B) CCL28–Ig binding. Left,
negative control; right, CCL28–Ig binding. (C) Total RNA was collected
from sorted mammary gland IgA ASCs. RT-PCR analysis shows expression
of the chemokine receptor CCR10 but not CCR3 on mammary gland
IgA ASCs.
Figure 3. Anti-CCL28 inhibits IgA ASC homing to the mammary
gland and IgA antibody accumulation in the milk. (A) Tissue sections
from the mammary gland of 9-d postpartum mice treated with anti-
CCL28 function-blocking antibody or isotype control antibody. Tissue
sections were stained with anti-IgA (green) and anti–TCR-  (red) anti-
bodies. The subiliac lymph node is included in the top region of each
photograph as a reference point. A magnification of 200. (B) Milk was
collected on days 1 and 9 postpartum from mice treated with anti-CCL28
or isotype control antibody. IgA, IgG1, and IgM levels in the milk were
determined. Horizontal bars represent the average of each group. Differ-
ences between IgA ASCs and IgA antibody accumulation between control
and anti-CCL28 treatment groups were statistically significant (P   0.001). 
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mary gland as well as the level of IgA antibody in the milk
on day 9 postpartum. Immunostaining of mammary tissue
sections revealed an almost complete inhibition of IgA ASC
accumulation in animals treated with anti-CCL28 (Fig. 3 A),
with an average of 1.8 IgA ASCs/mm
 
2 
 
compared with 28.9
IgA ASCs/mm
 
2 
 
in isotype control mAb-treated mice (P 
 
 
 
0.001). Importantly, antibody blockade of CCL28 substan-
tially inhibited IgA secretion into milk (Fig. 3 B). IgA anti-
body levels in milk collected 9 d postpartum from anti-
CCL28–treated animals were 
 
 
 
20 
 
 
 
g/ml, similar to IgA
serum (not depicted) and milk levels on day 1 postpartum, at
which time IgA ASCs in the mammary gland are infrequent
and the majority of IgA antibody is derived from the blood
(24). Conversely, IgA levels in the milk of control mice
were 
 
 
 
130 
 
 
 
g/ml (P 
 
  
 
0.001). Unlike IgA ASCs, most
IgG and IgM secreting cells do not migrate to the chemo-
kine CCL28 in vitro (14) and do not accumulate, in appre-
ciable numbers, in the mammary gland (18). The small
amount of IgG present in the milk is found at all stages of
lactation and is likely serum derived (24, 25). Accordingly,
levels of IgG
 
1
 
 and IgM in the milk were low in lactating
mice and remained unaffected by anti-CCL28 treatment
(Fig. 3 B).
 
CCL28 Blockade in the Mother Inhibits Passive Immune
Transfer to the Neonate.
 
Next, we asked whether CCL28
blockade in the mother significantly reduced maternal IgA
levels in the gastrointestinal tract of the neonate. Mothers
were treated with control antibody or anti-CCL28, and the
amount of IgA in the feces of nursing pups was determined
(Fig. 4). Newborn mice nursing on mothers treated with
isotype control antibodies had high levels of IgA antibody
in their stool (mean: 472.7 
 
  
 
53.7 
 
 
 
g antibody/mg feces).
Conversely, newborn mice nursing on mothers treated
with anti-CCL28 antibody had approximately sevenfold
lower levels of IgA in the stool (mean: 70.3 
 
  
 
14.1 
 
 
 
g an-
tibody/mg feces; P 
 
  
 
0.001).
In summary, we show that the mucosal epithelial che-
mokine CCL28 regulates the accumulation of IgA ASCs in
the lactating mammary gland, and is required for transfer of
maternal IgA antibodies to the suckling infant. In contrast
to its constitutive expression by intestinal, respiratory, and
salivary gland epithelium (19), CCL28 is not highly ex-
pressed in the resting mammary gland, but instead is dra-
matically up-regulated postpartum in association with the
onset of lactation. The up-regulation of CCL28 correlates
with an influx of large numbers of IgA-secreting cells.
Mammary gland ASCs, like IgA ASCs in other mucosal
sites and in blood, migrate efficiently to CCL28 in vitro
and express CCR10. In vivo, anti-CCL28 antibodies block
the postpartum accumulation of IgA-secreting cells in the
mammary gland, supporting the hypothesized role of CCL28
in the tissue recruitment of IgA plasma cells (14, 22, 26).
This blockade results in dramatically reduced levels of IgA
antibody in milk and in the gastrointestinal tract of the
nursing infant.
It has been proposed that IgA ASCs homing to diverse
mucosal surfaces creates a common mucosal immune sys-
tem (27, 28). Our data indicates that the chemokine
CCL28 can play an integral role in such a common mu-
cosal immune system by linking homing mechanisms be-
tween the gut, respiratory tract, and the mammary gland.
The “redirection” of IgA cells to the mammary gland is
controlled through the regulated expression of CCL28
during lactation, a process that enables the passive transfer
of maternal IgA antibody from the mother to the gut of the
immunologically naive newborn.
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